ImmuPharma (LON:IMM) Stock Price Down 11.6% - Time to Sell?

Key Points

• ImmuPharma's stock price fell by 11.6%, trading at GBX 15.55 ($0.21), after previously closing at GBX 17.60 ($0.24), with a notable increase in trading volume.
• The company reported a net margin of 3,519.56% but has a negative return on equity of 131.41%, indicating significant financial challenges.
• ImmuPharma is focused on developing peptide-based therapeutics, including its lead program Lupuzor™, aimed at treating autoimmune diseases like Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price traded down 11.6% on Tuesday . The stock traded as low as GBX 14.10 ($0.19) and last traded at GBX 15.55 ($0.21). 28,608,859 shares traded hands during mid-day trading, an increase of 241% from the average session volume of 8,383,843 shares. The stock had previously closed at GBX 17.60 ($0.24).

ImmuPharma Trading Down 11.6%

The stock has a market cap of £77.71 million, a P/E ratio of -1,747.19 and a beta of 1.53. The company's 50 day moving average price is GBX 3.43 and its two-hundred day moving average price is GBX 3.01.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.